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We recently surveyed the relationship between the human brain transcriptome and genome in a series of neuropathologically normal
postmortem samples. We have now analyzed additional samples with a conﬁrmed pathologic diagnosis of late-onset Alzheimer disease
(LOAD; ﬁnal n ¼ 188 controls, 176 cases). Nine percent of the cortical transcripts that we analyzed had expression proﬁles correlated
with their genotypes in the combined cohort, and approximately 5% of transcripts had SNP-transcript relationships that could distin-
guish LOAD samples. Two of these transcripts have been previously implicated in LOAD candidate-gene SNP-expression screens. This
study shows how the relationship between common inherited genetic variants and brain transcript expression can be used in the study
of human brain disorders. We suggest that studying the transcriptome as a quantitative endo-phenotype has greater power for discov-
ering risk SNPs inﬂuencing expression than the use of discrete diagnostic categories such as presence or absence of disease.Introduction
Our hypothesis is that genetic variation driving gene
expression is integral to the processes involved in normal
and pathogenic aging of the human cortex. In contrast to
polymorphisms that change the amino acid sequence of
genes, many single-nucleotide polymorphisms (SNPs)
that are responsible for changes in gene expression might
have more subtle phenotype effects that better explain
diseases with complex modes of inheritance, including
many diseases of late onset. We have performed whole-
genome genotyping and transcriptome-expression analysis
on a series of control and neuropathologically conﬁrmed
late-onset Alzheimer disease (LOAD) human brain samples
to uncover human-cortex expression quantitative trait loci
(eQTLs) that are relevant to both health and disease in the
aged brain.
eQTLs are genomic sequence variants (as determined
by genome-wide SNP analysis) that correlate with gene-
expression differences (as determined by transcriptome-
wide microarray experiments). eQTL studies are similar
to traditional genetic-association studies, but instead ofassociating genetic markers with discrete traits such as
disease status, eQTL studies correlate genetic markers
with quantitative gene-expression levels. It has been sug-
gested that this could be a powerful and complementary
approach to detection of novel risk loci.1 The outputs
from this type of screen are SNP-transcript pairs in which
gene expression is correlated with genotype in a dose-
dependent fashion.
Human genome- and transcriptome-wide eQTL analysis
has been employed in the study of diseases such as
asthma, cardiovascular disease, hypertension, and obesity
with the use of human EBV-transformed immortalized
B cell lines (ECLs2,3,4,5), as well as adipose5 and liver6
tissue. To our knowledge, other than our screen of control
brain,7 no eQTL studies using human cortical tissues have
been published. Recent tissue microarray surveys report
that a signiﬁcant proportion of the human transcriptome
is unique to the cortex;8,9 therefore, deﬁning the transcrip-
tome-genome relationship in health and disease through
the use of brain tissue is crucial for unlocking novel risk
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Subjects and Methods
Subjects
Our LOAD cohort was obtained concurrent to our control cohort7
from 20 National Alzheimer’s Coordinating Center (NACC) brain
banks and from the Miami Brain Bank (see Supplemental Data,
available online, for a list of sites). Our criteria for inclusion were
as follows: self-deﬁned ethnicity of European descent, neuropa-
thologically conﬁrmed LOAD or no neuropathology present, and
age of death greater than 65. We restricted the series to samples
with European ethnicity because there are known allele-frequency
differences between groups with different ethnicities and these
differences might distort our genomic SNP-screen results. Neuro-
pathological diagnosis was deﬁned by board-certiﬁed neuropa-
thologists as per standard NACC protocols. Samples that had a
clinical history of stroke, cerebrovascular disease, Lewy bodies, or
comorbidity with any other known neurological disease were
excluded. LOAD or control neuropathology was conﬁrmed by pla-
que and tangle assessment, 43% of the entire series having Braak
staging.10 Samples were de-identiﬁed before receipt, and the study
met local human studies institutional review board and HIPPA
regulations. This work is declared not human-subjects research
and is IRB exempt under regulation 45 CFR 46. We received a total
of 1174 tissue samples from the sites that replied to our request. Of
those samples, ~65% that met criteria were prepared for DNA and
RNA. Total sample counts equaled 486 LOAD cases and 279 neuro-
pathologically conﬁrmed controls. Of the plated DNA and RNA,
we chose ~60% for inclusion in this pilot study. Inclusion at this
stage was determined by assessment of RNA and DNA quality
through visual inspection on gels.
Genotyping and Expression Proﬁling
DNAwashybridized to the AffymetrixGeneChipHumanMapping
500K Array Set (502,627 SNPs) as previously described.11,12 Geno-
typeswere extractedwith the use of both SNiPer-HD13 andBRLMM
(Affymetrix, SantaClara,CA) algorithms.Genotypes that exhibited
less than98%concordance between callswere excluded. SNPswith
call rates less than 90% were excluded from the analysis. Hardy-
Weinberg equilibrium (HWE) was assessed with exact tests and
the PLINK analysis toolset.14 SNPs with HWE exact-test p values
less than 0.05, as well as SNPs with minor-allele frequencies less
than 1%,were excluded. Allele calls had amean of 97%and a range
of 90%–99%. cRNA was hybridized to Illumina Human Refseq-8
Expression BeadChip (24,357 transcripts) via standard protocols.
Expression proﬁles were extracted and rank invariant normal-
ized15–17 with the use of the BeadStudio software available from
Illumina, with the Illumina custom error model used. Rank-
invariant-normalized expression data were log10 transformed,
and missing data were encoded as missing, rather than as a zero
level of expression. Chips with average detection scores less than
0.99 (5% of control chips, 8% of LOAD chips) were excluded from
the analysis. Transcripts that were detected in less than 90% of
the case or 90% of the control series were excluded from our study.
This was amodiﬁed criterion fromour original report and included
36% of probes on the entire chip. This was done in an effort to
enrich for primary effects, particularly in the disease cohort. We
assessed correlations between 380,157 SNPs and 8650 transcripts.
Analysis
As in our prior report,7 we ran the genotypes from our cohort
concurrently in STRUCTURE,18,19 with seven other populations.446 The American Journal of Human Genetics 84, 445–458, April 10To determine the degree of relatedness between the samples in
our cohort, we used the pairwise IBS and IBD calculators available
in the PLINK analysis toolset.14 We plotted sample relatedness
data in R, and we used the cmdscale function within the stats
package to perform a multidimensional scaling analysis of the
matrix of genome-wide IBS pairwise distances. For veriﬁcation of
the reported gender of samples, the sex-check functionality in
the PLINK analysis toolset14 was used. Samples identiﬁed as
having a gender mismatch or gender ambiguity were excluded
from analysis.
Single-Locus Analysis
Prior to our analysis, transcript proﬁles were corrected for several
covariates by use of the R suite of programs. Expression proﬁles
were regressed against the sample data for several biological cova-
riates (gender, apolipoprotein E [APOE; MIM þ10774], allele dose,
age at death, and cortical region) and several methodological cova-
riates (day of expression hybridization, institute source of sample,
postmortem interval [PMI], and a covariate based on the total
number of transcripts detected in each sample). SNP genotype
was not included in this model, because we were interested in
covariate correction a priori to running our analysis. All covariates
except age at death, APOE 34 allele dose, and postmortem interval
were coded as factors for this analysis. All samples had complete
information for all covariates except PMI (n ¼ 10 LOAD samples,
1 control sample). Average PMI values were used for these samples.
Residuals from this analysis were employed in the single-locus
eQTL analysis.
To determine our single-locus eQTL effects, we regressed the
expression level of each transcript per sample on the number of
minor alleles (0, 1, or 2) for the 380,157 SNPs that met the cutoff
criteria. To capture both the effects that were independent
of disease status and the eQTL effects in which there was an effect
of disease, we included an interaction term for diagnosis in our
model. To allow for situations in which the eQTL effect differs
between LOAD cases and controls, we performed a two degree of
freedom (2 df) test comparing a model in which transcript expres-
sion depends on the additive effects of SNP and disease status,
together with their interaction term, against a model in which
expression depends only on disease status. Themain effect of diag-
nosis was included in the model for prevention of spurious associ-
ations occurring when SNP allele frequencies and overall expres-
sion levels differ independently between cases and controls.
Including the interaction term allows the slope of the regression
of expression on minor-allele dosage to differ between cases and
controls. Allowing for differences between cases and controls via
a 2 df test slightly reduces power for detection of SNP effects that
are independent of disease status; however, this method greatly
increases power for detection of effects that are disease speciﬁc.
Furthermore, analyzing the entire cohort together considerably
increases power as compared to performing separate tests in cases
andcontrols.Uncorrectedpvalueswere retained fromthis analysis.
Genome-wide signiﬁcance levels for each transcript were calcu-
lated by permutation of the subject labels, allowing for both non-
normality of the transcript data and linkage disequilibrium (LD)
among the SNPs. All permutated data sets were generated in the
same manner, through randomly permuting sample identiﬁers
in the transcript data (thus permuting all transcripts simulta-
neously). The replicate data sets were analyzed in the same way
as the real data. Permutation analysis was performed on the Trans-
lational Genome Research Institute’s IBM System Cluster 1350,
which contains a total of 1024 computing nodes and is housed
on the Arizona State University campus., 2009
To capture the relative contributions of our case and control
cohorts to the effects recovered in our 2 df model, we performed
individual analysis on each series. We analyzed the same model
without the diagnosis interaction term separately in cases and
controls. Signiﬁcance of effects was not determined in this
modeling; therefore, permutation corrections were not performed.
The correlation coefﬁcients from these analyses were extracted
with the use of the linear modeling (lm) functionality in R. The
adjusted correlation coefﬁcients (r2adj CO [controls] and r2adj
CA [cases]) represent the portion of the expression variance ex-
plained by the SNP in each cohort, and the beta values (b cases
and b controls) give the magnitude and direction of effects.
Fisher’s exact tests20 were employed for assessing associations
between SNPs and diagnosis status without considering expres-
sion proﬁles. These were implemented in PLINK14 and should
correct for cases in which the allele frequencies of tested SNPs
are sufﬁciently small as to make a chi-square test inappropriate.
To determine whether known SNPs mapped to the transcript
probes, thus creating a possible false positive through non-biolog-
ically relevant differential hybridization, we used the Hapmap
CEU data. Hapmap SNPs that were variable in the CEU cohort
were mapped with respect to the transcript probes. LD was deter-
mined by the r2 statistic, and the r2 values between the signiﬁcant
SNPwithin our screen and the SNPwithin the probe from the CEU
Hapmap data set were annotated within our results. It is presumed
that SNP pairs with higher LD are more likely to be putative false
positives if it is true that single SNP changes can affect the hybrid-
ization of the 50-mer transcript probes on the Illumina chips in
a way that is not biologically relevant. However, all data are re-
ported, because we have not made an independent assessment
of the SNP-within-probe effect.
Network Analysis
We incorporated both transcripts that were signiﬁcantly associ-
ated with allele dosage and those that were differentially expressed
between LOAD cases and controls in our analysis. Our eQTL data
set was deﬁned as transcripts with a SNP-transcript correlation p
value % 0.01 after 1000 permutations and a SNP effect that was
not in LD (r2R 0.8) with a polymorphism in the probe. Our differ-
entially expressed data set was deﬁned as transcripts identiﬁed
through signiﬁcance analysis of microarrays (SAM21) with a false
discovery rate (FDR) < 1%. We used HQCUT22 to form the
networks from residual corrected transcript data, the Database
for Annotation, Visualization and Integrated Discovery
(DAVID)23,24 to map gene ontologies to the clusters found by
HQCUT, and the Network Edge Orienting program (NEO)25 to
incorporate SNPs into these networks. We determined hub genes
by examining the distribution of the number of links per gene
(n ¼ 1697). The cutoff level for hub genes was determined by
the following formulae: Cutoff threshold ¼ m þ (2 3 S), in which
m is the mean number of links and S is the standard deviation.
Assessment of Disease-Specific Effects
We wanted to assess whether proﬁling a speciﬁc neuropatholog-
ical disease was important in our recovery of new effects or
whether these ﬁndings were simply a result of the increase in
power through the doubling of our sample size. This is an impor-
tant distinction, because for some diseases it might be difﬁcult to
sample from individuals with disease proﬁles; thus, knowing
whether disease effects can be captured in nondisease tissue is
important. To test this, we created a bootstrap control sample
with 364 subjects by using R to sample the genotype and covariate
data from the control portion of our data set with replacement and
introducing a small amount of random variation (smoothed boot-The Amstrap). We used PLINK14 to evaluate the association between the
minor-allele dose of each SNP and the transcript-expression level
in the bootstrap sample, using the same 2 df model that we em-
ployed in the original analysis. Only SNP-transcript pairs that
were signiﬁcant (2 df test, a ¼ 0.05) in our original analysis were
analyzed, and these were stratiﬁed on the basis of those that had
a signiﬁcant interactionpvalue (interaction terma¼0.05,n¼665)
and those that did not (interaction term a > 0.05, n ¼ 1820).
We then evaluated the proportion of SNP-transcript pairs that
were detected in the LOAD and control data set and could be
detected in the bootstrap control sample.
Replication
A portion of our SNP-transcript effects were replicated in our entire
series through Taqman real-time PCR.26Multiplex single-tube rela-
tive-quantiﬁcation measurements were obtained with the assays
Hs01028610_m1 (ITPKB [MIM 147522]) and Hs00907680_g1
(DKFZp566B183 [MIM 611623]). Primer-limited beta-2-microglo-
bulin was used as the endogenous control. Efﬁciencies from
simplex reactions were 97% for Hs01028610_m1 and 100% for
Hs00907680_g1. Comparison of target and endogenous delta-CT
values in simplex reactions showed similar efﬁciencies; the abso-
lute values for slopes from delta-CT plots verses log input plots
were less than < 0.1, justifying our use of the comparative delta-
delta-CT method. All values were obtained from averages of three
replicate reactions per sample. No-RT reactions for all assays were
negative. Fold-change values were calculated relative to a normal-
izer sample present on all plates. Fold changes were corrected for
all covariates with the use of R. Analysis was performed in PLINK
as before, with the use of the corrected residuals. Multiple test
adjustments were computed with a Dunn-Sida´k correction.27
Results
Sample
Table S1 gives all sample information. Two LOAD samples
(WGAAD-75 and WGAAD-270; see Figure S1) were found
to be ethnic outliers and were excluded from our analysis.
Samples were also screened for assessment of whether
they had some degree of relatedness, and all LOAD samples
were found to be unrelated. The following samples were
removed from the analysis because their genetically
predicted gender did not match their reported gender:
WGACON-105 (reported female appears to be male),
WGACON-108 (reported male appears ambiguous), WGA-
CON-212 (reported male appears ambiguous), WGAAD-
252 (reported male appears to be female), WGAAD-465
(reported male appears to be female), and WGAAD-479
(reported female appears to be male). Our total cohort
included 364 human brain tissue samples; 176 LOAD cases
and 188 controls after all exclusions.
Assessment of the expression proﬁles in the LOAD
cohort found that approximately 58% of the transcripts
on the Illumina Human RefSeq-8 Chip were expressed in
at least 5% of our LOAD cohort. This is the same portion
of the transcriptome that was found expressed in brain
in the control series, suggesting that there is not a major
skew in our LOAD-series proﬁles. Figure S2 graphs the
portion of signiﬁcant transcript effects (uncorrected a ¼
0.05) for each covariate in both the LOAD and the controlerican Journal of Human Genetics 84, 445–458, April 10, 2009 447
cohorts. Note that our largest effects were with hybridiza-
tion date (methodological covariate) and APOE status (bio-
logical covariate), other covariates having less of an effect.
PMI was the covariate that had the smallest effect on our
data.
Single-Locus Analysis
Cis effects and trans effects were deﬁned as described previ-
ously;7 cis associations were those that involved SNPs
within 1 Mb of the 50 end of the gene or 1 Mb of the 30
end of the gene and within the gene. This criterion was
utilized for consistency with our previous study. From
a practical perspective, it means that for each transcript,
~1% of the genome is deﬁned as cis and 99% as trans. It
is important to note that all analyses were performed
genome-wide, such that all SNPs irrespective of location
were run against each transcript and permutations were
performed to obtain genome-wide signiﬁcance. Thus, for
any of our SNP-transcript pairs, other deﬁnitions of cis
versus trans localizations can be applied, because our
signiﬁcance calculations do not rely on distance.
After correction with 1000 permutations, approximately
9% of the transcripts showed a genome-wide signiﬁcant
correlation with SNP genotype in the combined sample
of cases and controls (p % 0.05, 1000 permutations). We
identiﬁed 1829 SNP-transcript pairs with effects in cis in
the total cohort and 656 trans pairs, in which the SNPmap-
ped greater than 1Mb from the 50 or 30 end of the gene. We
found that 27% of all eQTL had a signiﬁcant interaction
with diagnosis. For each phase of our study, 37% of cis
LOAD-interacting candidate transcripts in this screen over-
lap with those found in our ﬁrst report, which considered
only control brains.7 The overlap with a large subset of
candidates found in the analysis of disease-free controls
suggests that end-stage neuropathological tissue does not
create a bias in expression proﬁling and that contributions
stemming from signal degradation and potential sampling
differences are minimal. This also suggests that within our
study, several of the SNP-transcript LOAD effects are risk
factors, much like the APOE E4 allele, and appear in
a portion of controls. For these effects, we assume that
within LOAD, there are additional environmental or unas-
sessed biological risk factors that cause predisposition to
LOAD. There is an 18% overlap with our previous report
considering both cis and trans results with no interaction
with diagnosis, and there is a 9% overlap with our previous
report considering all results with a positive interaction
term.
Figure 1 plots the log of the uncorrected p value (log
(p value)), the b values (slope), and the adjusted correlation
coefﬁcients (adjusted r2) versus distance from the tran-
scription start site (TSS) for all of our cis effects. Many of
our cis effects mapped far downstream or upstream of the
TSS (Figure 1A). Although it is possible that there are regu-
latory elements that act over such long distances, ﬁner
mapping will need to be performed for determination of
the extent to which they are true effects and of the extent448 The American Journal of Human Genetics 84, 445–458, April 10to which they reﬂect LD in these regions. In Figures 1B and
1C, it is of note that the size of effect is inversely propor-
tional to the distance from the TSS, as measured by either
the proportion of variance explained (Figure 1B) or the
slope (Figure 1C). This suggests that it is probable that
true effects map close to the TSS. We found approximately
as many cis negative correlations (minor allele is high
expresser) as cis positive correlations (major allele is high
expresser), greater differences being found between the
alleles mapping closer to the TSS (see Figure 1C). Table 1
lists the top eQTL results in which there was a signiﬁcant
interaction with diagnosis, and Table 2 lists the top eQTL
results in which there appeared to be no diagnosis effect.
All results are listed in Tables S5 and S6.
Although each SNP-transcript pair is unique to either the
LOAD-interacting data set (Table 1, Table S5) or the nonin-
teraction data set (Table 2, Table S6), some of our transcripts
overlap between these lists. For our top results in Tables 1
and 2, abhydrolase domain-containing 12 (ABDH12), an-
kyrin repeat domain 27 (ANKRD27), ninein-like protein
(KIAA0980, [MIM *609580]), kinesin family member 1B
(KIF1B, [MIM *605995]), inorganic pyrophosphatase 2
(PPA2, [MIM *609988]), and peptidylprolyl isomerase-like
protein 3 (PPIL3) all occur on both Table 1 (diagnosis inter-
action effect) and Table 2 (no interaction). To investigate
why this overlap is occurring, we examined the SNPs
mapping to these transcripts and found two effects. In the
ﬁrst case, the main effect appears to be with diagnosis, but
some SNPs just missed our cutoff for having a signiﬁcant
interaction term(a¼0.05). For SNPs inABDH12,ANKRD27,
KIAA0980, and KIF1B, as the LD between the main-effect
SNPs in Table 1 and the additional SNPs in the gene gets
weaker, the signiﬁcance of the interaction term erodes until
it slipsbelowoura¼0.05cutoff, causing these subthreshold
lower-LDSNPs tooccur inTable 2. In the secondcase, for the
transcripts PPA2 and PPIL3, there are actually separate LD
blocks that both contain eQTL SNPs, but only one of the
blocks has a signiﬁcant interaction term. In this situation,
two separate eQTL effects are observed for the single tran-
script, and only one of them has a signiﬁcant interaction
with LOAD. This effect is biologically plausible in that
SNPs in each block might be changing different transcrip-
tion-factor binding sites, one of which is implicated in
LOAD risk and the other of which is not.
Network Analysis
In our original report, each transcript was treated as a single
unit and run against the SNP proﬁles for the entire
genome. This type of analysis does not consider the inter-
dependence of transcript proﬁles or the network of effects
that might occur within the human brain. To capture this
additional information, we performed an initial network
analysis of a subset of our eQTL transcripts. For this anal-
ysis, we also included transcripts for which there was no
correlation of expression with genotype but was a signiﬁ-
cant difference in transcript expression between cases
and controls. This would help in determining whether, 2009
Figure 1. Cis Association Metrics Versus Distance from Transcription Start Site
Plotted on the x axis is the distance from the TSS mapped on the human genome build 36. y axis metrics are given, with slope in Figure 1C
corresponding to the b values from the correlations. Note thatlog(p value) values were calculated in the 2 df model with the use of the
entire series, whereas the b values and the adjusted correlation coefficients were calculated separately in cases and controls, but all
values are plotted.there were additional effects of our eQTL on downstream
expression that were relevant to disease and would not
be captured in a single-locus analysis.
Of the transcripts we used for our network analysis,
~27% were signiﬁcantly correlated with minor-allele dose
(eQTL data set deﬁned by 1000 permutations, a ¼ 0.01).
The remaining transcripts were included because they
were deﬁned as being differentially expressed through
signiﬁcance analysis of microarrays (SAM21) with an FDR
cutoff % 0.1% (differentially expressed [DE] data set).
The HQCUT algorithm recovered nine clusters in this
data set. Ten transcripts did not cluster within the network.
These transcripts were all from our eQTL data set. Figure 2
shows the resulting adjacency matrix. Table 3 gives
summary statistics for each cluster, including the majorThe Amontology group mapped with the DAVID annotation for
each cluster.23,24 The full list of top ontology keywords
for each cluster is given in Tables S2A and S2B. Several of
these ontology groupings matched results from previous
LOAD-expression-only screens.28
To further assess our network, we examined whether any
transcripts within the network had an overrepresentation
of links to other transcripts (‘‘hub genes’’), suggesting
that they were controlling many downstream effects. The
essential nature of hub genes has been demonstrated
within studies using yeast.29 In our data set, the mean
number of links in our network was 56 and the standard
deviation was 38.78; thus, our cut off was 134 links, which
is indicated in Figure S3.Within our eQTL andDE network,
there were 62 hub genes, which are shown in Table 4.erican Journal of Human Genetics 84, 445–458, April 10, 2009 449
Inter p Valuel r2 CAm r2 COn Dir.o
3.770 3 102 0.44 0.38 þ
4.160 3 102 0.17 0.31 -
7.080 3 107 0.13 0.05 þ/
9.490 3 104 0.12 0.04 -
4.520 3 102 0.04 0.13 -
2.900 3 102 0.08 0.27 -
3.440 3 106 0.14 0.05 /þ
1.050 3 106 0.15 0.05 /þ
7.120 3 102 0.01 0.13 þ
5.820 3 104 0.24 0.41 þ
3.110 3 102 0.15 0.01 -
4.230 3 102 0.14 0.33 -
1.270 3 102 0.24 0.14 -
2.990 3 103 0.12 0.05 -
2.580 3 102 0.29 0.15 þ
3.530 3 102 0.5 0.41 -
3.120 3 102 0.48 0.27 þ
1.090 3 103 0.12 0.04 -
1.050 3 103 0.13 0.04 -
3.550 3 105 0.04 0.32 -
3.380 3 102 0.27 0.1 -
2.800 3 102 0.21 0.02 -
2.470 3 102 0.02 0.13 -
2.740 3 102 0.51 0.33 þ
1.790 3 103 0.14 0.05 þ
1.760 3 103 0.13 0.04 þ/
2.330 3 102 0 0.14 þ
2.510 3 102 0.12 0.02 þ
diagnosis interaction term. Listed is a subset of the
irical p value from 1000 simulations% 0.05, gene-
eQTL SNP and any polymorphism in probe (r2< 0.8),
d in alphabetical order. All data are also representedTable 1. Top Transcript-SNP Pairs with a Significant Effect of Diagnosis
Probe IDa Symbolb Chr.c Bp Positiond Best SNPe S_Chr.f S_Pos.g Otherh Loc.i Raw p Valuej 1K p Valuek
GI_34147330-S ABDH12 20 25.2–25.3 rs6050598 20 25.3 40 cis 1.540 3 1065 9.990 3 104
GI_14149802-S ANKRD27 19 37.8–37.9 rs259228 19 37.8 13 cis 1.190 3 1031 9.990 3 104
GI_14916517-S AP3M1 10 75.6 rs26133 5 14.2 1 trans 3.280 3 109 1.500 3 102
GI_38261968-S APG12L 5 115.2 rs2483589 10 116.4 1 trans 7.930 3 109 2.000 3 102
GI_29739147-S ARL16 17 77.3 rs6565624 17 77.3 3 cis 4.360 3 1012 9.990 3 104
GI_38327635-S C14orf4 14 76.6 rs1120277 14 76.5 0 cis 1.840 3 1027 9.990 3 104
GI_23346408-S C20orf111 20 42.3 a-2038955 1 19.6 0 trans 2.040 3 109 2.000 3 102
GI_25092657-S C7orf27 7 2.5–2.6 rs3936086 16 13.6 1 trans 5.520 3 109 1.600 3 102
GI_37059735-S CWF19L1 10 102 rs11594333 10 101.9 6 cis 4.650 3 1011 9.990 3 104
GI_39995081-S FLJ20303 5 6.7 rs4701742 5 66.7 10 cis 1.180 3 1051 9.990 3 104
GI_32698961-S GDPD1 17 54.7 rs7223491 17 54.6 5 cis 5.770 3 1015 9.990 3 104
GI_30061497-I GGTL3 20 32.9 rs6087619 20 32.8 23 cis 2.220 3 1033 9.990 3 104
GI_22095346-S IGSF4 11 114.5–114.9 rs7125361 11 114.6 5 cis 3.020 3 1026 9.990 3 104
GI_29171690-I ILVBL 19 15.1 rs11851301 14 94.2 0 trans 1.780 3 109 5.990 3 103
GI_37059782-S KIAA0980 20 25.4–25.5 rs6132819 20 25.2 35 cis 1.750 3 1029 9.990 3 104
GI_41393558-I KIF1B 1 10.2–10.4 rs12120191 1 10.3 22 cis 1.530 3 1079 9.990 3 104
GI_42658911-S LOC401470 8 93.2 rs11171739 12 54.8 5 trans 4.540 3 1058 9.990 3 104
GI_38455399-S MADH5 5 135.5 rs2483589 10 116.4 1 trans 3.010 3 108 2.100 3 102
GI_5174552-S MFAP1 15 41.9 rs17546037 5 7.3 1 trans 7.340 3 109 5.990 3 103
GI_7662347-S MONDOA 12 121.0–121.2 rs3741452 12 121.2 1 cis 2.620 3 1028 9.990 3 104
GI_31881619-A PPA2 4 106.5–106.6 rs2866799 4 106.7 19 cis 1.260 3 1024 9.990 3 104
GI_45439315-I PPIE 1 40 rs1180341 1 39.8 2 cis 3.260 3 1014 9.990 3 104
GI_19557635-A PPIL3 2 201.4–201.5 rs6715380 2 201.9 14 cis 2.340 3 1012 9.990 3 104
GI_15011935-S RPS26 12 54.7 rs11171739 12 54.8 5 cis 1.150 3 1070 9.990 3 104
GI_7657430-S SND1 7 127.1–127.5 rs1408015 13 106.9 1 trans 3.150 3 108 3.800 3 102
GI_5730084-S TCTEL1 6 159 rs10843090 12 28.1 0 trans 1.430 3 108 3.000 3 102
GI_8922751-S TYW1 7 66.1–66.3 rs6966142 7 66 8 cis 1.180 3 1012 9.990 3 104
GI_41281748-I ZNF323 6 28.4 rs149970 6 28.1 8 cis 8.350 3 1010 6.990 3 103
This table shows the list of transcript-SNP pairs that had transcript-specific empirically significant p values by our 2 df model and where there was a significant
effects, generated from the full list of associated transcript-SNP pairs (Table S5). Criteria for generation of subset includes: transcript-specific 2 df model emp
expression detection rate within both cases and controlsR 99%, SNP call rateR 99% overall, minor-allele frequencyR 5% in cases and controls, no LD between
and SNP accounting for 12% or greater of the variance in transcript expression in either cases of controls (adjusted r2 in cases or controlsR 0.12). Genes are liste
in Table S5.
a GI illumina probe identifiers.
b Correlated transcripts.
c Transcript chromosome.
d Transcript position (listed in Mb).
e SNP with the smallest 2 df model–corrected (1000 permutations) p value for that transcript (dbSNP or Affymetrix identifiers listed).
f SNP chromosome.
g SNP position (listed in Mb).
h Number of other SNPs with a 2 df model p value for the transcript that was significant after 1000 permutations (a ¼ 0.05).
i Where the SNP was in cis or trans to the transcript.
j Uncorrected p value for the 2 df model.
k p value after correction of the 2 df model using 1000 permutations.
l p values for the interaction term in the 2 df model.
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Further examination of our network analysis found that
proportionally, most of our eQTLs were located in clusters
5 (44%), 2 (42%), and 3 (40%). Thirty-four percent of
cluster 2 transcripts had a signiﬁcant interaction with diag-
nosis with at least one SNP, a higher proportion than any
other cluster (see Table 3). From at our list of hub effects
(see Table 4), 6% of LOAD eQTL transcripts in cluster 2
had greater than 134 genes linked to them, a greater
portion of hub transcripts than in any other cluster.
Thus, for clarity in this preliminary report, we focused on
cluster 2; however, all data are available for analysis on
the additional clusters (see Web Resources). To analyze
this cluster, we used the program NEO.25 We used SNPs
to anchor the edges of the network and infer causal rela-
tionships between pairs of coregulated transcripts. A
portion of the resulting network is diagrammed in Figure 3.
Taqman Replication of Effects
For our data sets, we have replicated several effects via other
methodologies. First, within these samples, we had previ-
ously shown that expression of the Microtubule-Associated
Protein Tau gene (MAPT [MIM þ157140]) is affected by
SNPs mapping to the gene, by using qRT-PCR.30 Analysis
of our data from the genome-wide screen is consistent with
our previous data on these samples, in that alleles that occur
on the major haplotype of MAPT (H1) are associated with
higher Tau transcript expression. This provides an internal
positive control within our full-genome screen in that look-
ing genome-wide, we can ﬁnd effects that we have seen in
candidate-gene analysis of our samples. Additionally, we
have replicated our SNP-transcript-diagnosis relationship
for ITPKB and rs12125724 (Dunn-Sida´k-adjusted 2 df test p
value ¼ 2.763 104) by using Taqman assays and the same
model that we applied to the whole-genome and transcrip-
tome data; however, for DKFZp566B133 and rs9309291,
our Taqman analysis results did not survivemultiple testing
correction.
Candidates—cis eQTL
In terms of LOAD-speciﬁc effects, two LOAD candidate-
gene studies have been performed, examining SNP varia-
tion and gene expression. We have replicated both of these
results; however, more work clearly needs to be done in
independent series for determination of whether a greater
portion of our results replicate. In the ﬁrst candidate study,
Lambert et al.31 examined the Transcription Factor CP2
gene (TFCP2/LBP-1c/CP2/LSF [MIM 189889]) and found
that a SNPwithin the 30 UTR of the gene had a genetic asso-
ciation with LOAD risk. Additionally, this report examined
expression in lymphoblasts from patients genotyped for
the 30 UTR polymorphism and found that absence of the
A allele at this site was associated with a lower transcript
expression. In our screen, although we did not obtain
a signiﬁcant association by considering only SNP geno-
types localized to this gene, we did obtain a signiﬁcant
eQTL effect when considering expression in combination
with genotype and diagnosis.m
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Inter p Value r2 CA r2 CO Dir.
5.2030 3 102 0.43 0.38 þ
7.0820 3 101 0.34 0.32 -
2.0130 3 101 0.25 0.13 -
1.3840 3 101 0.23 0.31 þ
3.374 3 101 0.23 0.19 þ
5.860 3 101 0.29 0.20 -
6.905 3 101 0.48 0.45 þ
7.053 3 101 0.24 0.19 -
5.377 3 102 0.27 0.17 þ
2.428 3 101 0.31 0.27 þ
8.820 3 102 0.43 0.40 -
2.312 3 101 0.12 0.21 -
7.537 3 101 0.24 0.20 -
2.113 3 101 0.25 0.15 þ
4.611 3 101 0.26 0.31 þ
7.180 3 102 0.27 0.26 -
3.401 3 101 0.23 0.23 -
2.100 3 101 0.31 0.19 -
6.832 3 101 0.22 0.18 -
4.383 3 101 0.23 0.12 -
7.720 3 101 0.20 0.24 þ
6.109 3 101 0.25 0.31 -
9.318 3 101 0.24 0.18 þ
8.078 3 101 0.22 0.20 -
6.970 3 101 0.29 0.19 -
1.424 3 101 0.34 0.26 -
1.721 3 101 0.32 0.14 þ
5.155 3 102 0.25 0.09 -
6.325 3 101 0.25 0.23 -
2.506 3 101 0.42 0.40 -
3.116 3 101 0.43 0.46 þ
9.659 3 101 0.20 0.21 -
5.462 3 101 0.33 0.26 -
nosis interaction term. Criteria for selection of the
ll data set is available in Table S6. All headers are as
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9Table 2. Top Transcript-SNP Pairs without a Significant Diagnosis Interaction
Probe ID Symbol Chr. Bp Position Best SNP S_Chr S_Pos Other Loc. Raw p Value 1K p Value
GI_34147330-S ABDH12 20 25.2–25.3 rs4815412 20 25.3 40 cis 6.890 3 1064 9.990 3 104
GI_8923854-A AD-017 3 52.7 rs1961958 3 52.6 31 cis 1.450 3 1053 9.990 3 104
GI_22748838-S AHSA2 2 61.3 rs720201 2 61.2 19 cis 8.940 3 1024 9.990 3 104
GI_14149802-S ANKRD27 19 37.8–37.9 rs438268 19 37.8 13 cis 1.840 3 1036 9.990 3 104
GI_23238227-S CHST7 X 46.3 rs760697 X 46.3 3 cis 1.890 3 1023 9.990 3 104
GI_25306276-S EFG1 3 159.8–159.9 rs9832803 3 159.9 7 cis 1.420 3 1034 9.990 3 104
GI_31542792-S FN3K 17 78.3 rs11078015 17 78.4 16 cis 3.130 3 1079 9.990 3 104
GI_24431963-S HBS1L 6 135.3–135.4 rs4646871 6 135.3 15 cis 1.080 3 1027 9.990 3 104
GI_37059782-S KIAA0980 20 25.4–25.5 rs2258719 20 25.2 35 cis 1.860 3 1028 9.990 3 104
GI_21314694-S KIAA1449 3 39.1 rs811971 3 39.1 22 cis 5.080 3 1039 9.990 3 104
GI_41393558-I KIF1B 1 10.2–10.4 rs10492972 1 10.3 22 cis 1.650 3 1066 9.990 3 104
GI_4826813-A KTN1 14 55.1–55.2 rs10137340 14 55.1 4 cis 2.650 3 1023 4.995 3 103
GI_24308385-S LOC115294 8 52.9 rs17212214 8 53 21 cis 2.020 3 1028 9.990 3 104
GI_37546921-S LOC339804 2 61.2 rs720201 2 61.2 13 cis 1.590 3 1025 9.990 3 104
GI_40786403-S LOC374969 1 43.0–43.1 rs323720 1 43 12 cis 6.260 3 1037 9.990 3 104
GI_28603839-S MGC10120 10 102 rs6584356 10 102 3 cis 9.020 3 1037 1.998 3 103
GI_33859747-S MGC2752 19 63.8 rs10413586 19 63.8 1 cis 3.940 3 1032 9.990 3 104
GI_31652223-A MRPL21 11 68.4 rs478647 11 68.5 10 cis 1.850 3 1035 9.990 3 104
GI_28872733-I MRPL43 10 102.7 rs4917916 10 102.7 5 cis 1.520 3 1023 9.990 3 104
GI_29826284-A MRPL47 3 180.8 rs10513762 3 180.8 2 cis 1.750 3 1025 9.990 3 104
GI_6912539-S NUBP2 16 1.8 rs3848348 16 1.8 18 cis 9.170 3 1031 9.990 3 104
GI_40288186-A PDLIM2 8 22.5 rs2291232 8 22.5 11 cis 8.470 3 1043 9.990 3 104
GI_30179910-A PILRB 7 99.8 rs1000215 7 99.4 6 cis 4.330 3 1028 9.990 3 104
GI_31881619-A PPA2 4 106.5–106.6 a-1897043 4 106.5 19 cis 3.770 3 1028 9.990 3 104
GI_19557635-A PPIL3 2 201.4–201.5 rs10205561 2 201.5 14 cis 2.210 3 1032 9.990 3 104
GI_28274698-S RAB3IP 12 68.4–68.5 rs11177823 12 68.4 3 cis 1.280 3 1044 9.990 3 104
GI_14149701-S RNF167 17 4.8 rs238237 17 4.4 4 cis 2.600 3 1029 9.990 3 104
GI_4506738-S RPS6KB2 11 67 rs1476792 11 67 2 cis 1.990 3 1021 9.990 3 104
GI_34147665-S STK25 2 242.1 rs3755400 2 242 1 cis 2.170 3 1031 9.990 3 104
GI_6912707-S TIMM10 11 57.1 rs2729371 11 57.1 6 cis 1.590 3 1072 9.990 3 104
GI_15451941-S UBA52 19 18.5 rs1468475 19 18.5 6 cis 3.550 3 1081 9.990 3 104
GI_4557872-S UROS 10 127.5 rs1571278 10 127.5 14 cis 7.880 3 1028 9.990 3 104
GI_37622342-A ZNF266 19 9.4 rs4804436 19 9.4 23 cis 6.870 3 1044 9.990 3 104
This table lists transcript and SNP pairs that had transcript-specific empirically significant p values by our 2 df model and where there was a nonsignificant diag
subset is as described in Table 1, except that the SNP had to account for greater than 20% of the variance in transcript expression in either cases or controls. The fu
described in Table 1.
Figure 2. Adjacency Matrix of the eQTL and DE Network
Figure 2A shows the adjacency matrix for our HQCUT network analysis. Modules in this figure are labeled c1–c9. Genes are listed by map
number (1–1697) that was assigned during the clustering procedure and is arbitrary. Dots represent inter- and intramodule relationships
between transcripts. Figure 2B shows the number of transcripts per cluster.Our second LOAD hit that has been implicated in prior
studies is the glutathione-S-transferase (GSTO 2 [MIM
612314]) locus on chromosome 10q. This gene maps
within a linkage peak found in many family-based LOAD
linkage screens (for meta-analysis, see Hamshere et al.32)
and thus was studied as a LOAD candidate gene by Li
and colleagues.33 Their approach was slightly different
than a standard eQTL, in that they did not map expression
proﬁles directly in the linkage pedigrees but instead per-
formed expression proﬁling on separate samples and
then looked for differentially expressed genes that mapped
within linkage peaks and followed those candidates. They
found associations with SNPs both in GSTO 1 (p ¼ 0.007
[MIM 605482]) in and GSTO 2 (p ¼ 0.005), both of which
are tightly linked on chromosome 10, but onlyGSTO 1was
differentially expressed. We did not see a signiﬁcant eQTL
result with GSTO 1, and our analysis examining only
expression failed to detect differential expression at this
locus. We did see a GSTO 2 effect that had a signiﬁcant
interaction with diagnosis. Running the GSTO 2 Illumina
Chip hybridization probe through Blat to determine
whether there was cross-talk between GSTO 1 and GSTO 2
with respect to our hybridization signal yielded a single
hit in the entire genome, mapping speciﬁcally to the 30
UTR of GSTO 2. Given that the Li et al. study expression
proﬁling was performed in a separate cohort that was just
3% of the size of this one (n ¼ 6 LOAD, 2 control brains)
and that we performed our expression and genotyping
using the same cohort, we feel that it is likely that the
true effect at this locus on chromosome 10q is with
GSTO 2. This speaks to the power of examining bothThe Amexpression and genotypes in the same cohort because
correlations will detect linear relationships with gene
dosage, a method more powerful and accurate than simply
looking at gene expression alone. Additionally, trans effects
will be captured only by examining the relationship
between SNPs and expression together and will be missed
if SNPs and transcripts are assessed as separate data sets.
Finally, in both our control screen and our analysis of the
entire cohort, we replicated a result from one of the ﬁrst
published eQTL screens using EBV-transformed lympho-
blasts from the Centre d’Etude du Polymorphisme Hu-
maine (CEPH) cohort.34 This study, using different plat-
forms for whole-genome and transcriptome analysis than
those used in our analysis, found one transcript that had
a similar cis association. This transcript was ribosomal
protein S26 (RPS26 [MIM 603701]), which encodes a ribo-
somal protein that is a component of the 40S subunit. For
RPS26, Cheung and colleagues reported signiﬁcant associ-
ation with marker rs2271194, which is in complete LD
with two out of our six associated SNPs. This replicated
result suggested that this SNP-transcript pair is unlikely
to be a false positive. Additionally, twomore recent screens
have also found an effect with RPS26, further validating
the result.2,6 One of those studies, using human liver
samples, has implicated RPS26 in diabetes pathways,6
and we have found it to have a signiﬁcant interaction
with diagnosis in our screen. These observations suggest
that the function of ribosomal proteins might not be
limited to stability and efﬁciency of the ribosome. Ribo-
somal proteins may participate in the regulation of speciﬁc
transcripts or families of transcripts being processed by theerican Journal of Human Genetics 84, 445–458, April 10, 2009 453
ribosome, and many of those might be integral to disease
processes.35
Candidates—trans eQTL
Although it is more difﬁcult to capture validated trans
effects because of the fact that there are no distance limita-
tions placed upon their discovery, some trans effects are
likely to be real and of great interest for disease. Conceptu-
alization of how trans effects could occur is less obvious
than that of cis effects, but it is important to remember
that our screen captures only the expression proﬁles of
poly-A tailed mRNA. Thus, trans effects could be occurring
because the trans SNP is affecting an intermediary (such as
miRNA) that we have not captured within our screen.
Another possible scenario is that trans effects occur though
interchromosomal relationships in transcription ofmRNA.
Nunez and colleagues used chromatin-conformation
capture to demonstrate that interchromatin pairing of
disparate DNA sequences (in their example genes on chro-
mosomes 21 and 2) is a common feature of estrogen
receptor-a-mediated transcription.36 Thus, there could be
direct action of trans SNPs on target transcripts located
on different chromosomes.
Our network analysis is informative for assessing the
trans effects in our screen. In our preliminary analysis we
focused on cluster 2, because this cluster contained the
Table 3. Summary Statistics for the eQTL and DE Network
Cluster Total eQTL LOAD Top Process Score Count p Value
1 8% 16% 7% *organ
morphogenesis
1.72 8 2.900 3 103
2 4% 42% 34% zinc finger,
C2H2 type
0.99 8 4.100 3 103
3 6% 40% 12% cell growth 1.12 5 2.400 3 102
4 20% 33% 16% *negative
regulation of
transcription,
DNA dependent
2.05 13 2.400 3 103
5 6% 44% 19% protein kinase
cascade
2.06 9 2.200 3 103
6 9% 12% 9% KRAB box 2.11 9 5.500 3 105
7 19% 21% 10% ligase activity,
forming carbon-
nitrogen bonds
1.78 12 6.400 3 103
8 14% 35% 15% mitochondrion 3.02 33 8.200 3 106
9 14% 19% 10% glycoprotein 3.42 49 3.900 3 106
Shown are the proportion of transcripts, out of the total number of tran-
scripts networked, that map to each cluster (Total), that had a significant
(corrected p value < 0.05 after 1000 permutations) correlation with allele
dose (eQTL), and that had significant interaction term in the 2 df model
(LOAD). Top processes were defined as ontology groups that had the lowest
p value within the annotation cluster with the highest enrichment score.
The exception to this definition is indicated by an asterisk; for clusters 1
and 4, all of the ontology groups within the top enrichment-score bin
were the same for these two clusters (see Table S2B for ontology groupings
in this set). Therefore, for these clusters, top processes are listed within the
next most significant grouping of ontologies. Enrichment scores (Score),
numbers of transcripts within the top annotation cluster (Count), and p
values for the EASE scores for each process (p Value) are given. Table S2A
lists all top ontologies for each cluster.454 The American Journal of Human Genetics 84, 445–458, April 10highest proportion of transcripts that had LOAD eQTL
relative to the other clusters. Within this network, the
main effects were with the transcript C6orf29 (171 links
total, 58 links within cluster 2, accounting for 90% of the
cluster [OMIM 606107]) and the SNP rs9309291 (signiﬁ-
cant effect with 63 transcripts; all effects had a signiﬁcant
interaction with diagnosis, and ten of those transcript
mapped to cluster 2). C6orf29 is a member of a family of
three transporters, one of which was cloned because of
its ability to suppress a yeast choline transport mutation.37
Although currently the best LOAD biomarker is beta-
amyloid (for review see study by J. Hardy38), it has been
proposed that cholinergic systems are involved in Alz-
heimer disease.39 It is known that cholinergic neurons
are particularly susceptible to Alzheimer disease pathogen-
esis, further implicating this network in the pathogenesis
of LOAD. Thus, C6orf29 is a putative trans target in our
screen.
Discussion
We have performed a genome- and transcriptome-wide
screen to assess the downstream effects of risk variation
for LOAD on mRNA expression. The importance of work
and data is clear.
First, by focusing on a quantitative endo-phenotype
(expression) as opposed to a discrete phenotype (diag-
nosis), we have considerable power to detect subtle regula-
tory effects in a relatively small cohort. Statistical calcula-
tions have predicted that sample sizes on the order of
100 are sufﬁcient for 80% power for eQTL studies.40 This
is an order of magnitude less than that predicted for
genome-wide association studies (GWAS).41 We can clearly
see this by comparing this current analysis to our previous
GWAS.11 The cohort in this report was a part of our larger
GWAS sample and is approximately one-quarter the
sample size of that report (n ¼ 1411 in Reiman et al.,11
364 samples in this study). In our GWAS screen with an
unstratiﬁed analysis, our only result after correction for
multiple testing was with APOE.12 With rank ordering of
our uncorrected GWAS p values, it is of note that 6% of
our permutation-corrected eQTL SNPs fall within the top
5% of our uncorrected GWAS effects. Given that these
effects were statistically signiﬁcant in the smaller eQTL
cohort but not in the larger GWAS screen, eQTL quantita-
tive analysis might be more powerful for detection of
expression effects than discrete trait analysis. Of course,
this does not obviate the need for large GWAS studies,
because our approach would not capture coding changes
or other types of risk variants not associated with changes
in expression; however, it is clear that eQTL approaches in
smaller cohorts can capture regulatory risk effects that
would be found only in GWAS screens of considerably
larger size.
Second, assaying the tissue relevant to the disease of
interest is crucial. Expression studies proﬁling different, 2009
Table 4. Table of Hub Transcripts in the eQTL and DE Network
Cluster Probe ID Name Entrez No. Links
2 GI_37620215-S LOC253827 253827 134
4 GI_21314672-S CLST11240 51751 134
2 GI_34577082-A RSU1 6251 136
4 GI_4505876-A PLEC1 5339 136
7 GI_29740938-S KIAA1136 57512 136
7 GI_4504482-S HPRT1 3251 136
8 GI_4505718-S PEX11B 8799 136
7 GI_4503064-S CRYM 1428 137
2 GI_21389426-S MGC29891 126626 138
4 GI_34577104-A RNPC1 55544 138
4 GI_4758085-S CSRP1 1465 138
7 GI_27734858-S LOC285533 285533 139
7 GI_37221176-S NUDT11 55190 139
3 GI_34222376-S MGC44287 340547 142
4 GI_41152085-S SERPINB6 5269 142
4 GI_4508040-S ZNF91 7644 142
7 GI_21264573-S TM4SF13 27075 143
4 GI_13899238-S MGC10812 54858 144
3 GI_37538660-S IPLA2(GAMMA) 50640 146
4 GI_27754195-S MTND3 4537 146
4 GI_31982916-S FLJ23042 5829 146
4 GI_34147573-S ITGB5 3693 146
4 GI_8922566-S FLJ10647 55194 146
4 GI_31543199-S C7orf21 83590 147
2 GI_33589825-S APG10L 819941 148
3 GI_31543151-S MGC14817 84298 148
4 GI_38569399-S ITPKB 3707 148
4 GI_4755133-S DOK1 1796 149
4 GI_6005923-S TU3A 11170 149
1 GI_37550007-S KIAA0121 9686 150
3 GI_41393596-S CSAD 51380 150
1 GI_38788287-S ZNF160 90338 151
4 GI_19923329-S CTDSP2 10106 151
1 GI_28558992-I TG737 8100 153
4 GI_24308106-S DKFZp566C0424 26099 153
7 GI_21361148-S RGS7 6000 155
4 GI_38176295-I LASS1 10715 156
8 GI_34335244-A NMNAT2 23057 156
4 GI_11968040-S DCLRE1C 64421 158
4 GI_30795118-A FBXO18 84893 159
8 GI_19913427-S ATP6V1B2 526 159
1 GI_8922963-S SYNJ2BP 55333 163
4 GI_13376551-S FLJ14346 80097 163
4 GI_24308252-S DTX2 113878 163
4 GI_25453471-A EEF1D 1936 164
4 GI_4755141-S INPPL1 3636 168
2 GI_14249467-I C6orf29 80736 171
1 GI_14249445-S FLJ14431 84869 175
8 GI_23111022-S SNX10 29887 177
8 GI_10863934-S RTN1 6252 178
4 GI_19923612-S FLJ21128 80153 179
3 GI_42655861-S KIAA0492 57238 180
4 GI_19913359-S TBL1X 6907 180
4 GI_5803097-S MYST3 7994 182
8 GI_31542527-S DKFZP566B183 25977 186
1 GI_36030972-S UBXD4 165324 188
4 GI_38569463-S SASH1 23328 195
8 GI_20357538-A ATP6V1G2 534 202
8 GI_5454069-S SLC9A6 10479 202
4 GI_28558997-A PTBP1 5725 209
8 GI_45238856-S LOC114928 114928 214
4 GI_27478393-S LOC285919 285919 230The Amehuman tissues have shown that the human brain transcrip-
tome is unique.8,9 Additionally, recent eQTL work exam-
ining phenotypes involved in body mass found that there
was an order of magnitude difference between the effects
that they found by transcriptome sampling in blood verses
adipose tissue, many more signiﬁcant traits being found in
adipose, their tissueof interest.5Weare focusedonneurode-
generative disease; therefore, we have sampled brain tissue.
A possible argument could be put forth that postmortem
tissue does not have relevance for disease in living subjects;
however, recent in vivo work proﬁling MAPT in human
cerebral spinal ﬂuid and examining the relationship
between Tau levels and MAPT genotype has recapitulated
our ﬁndings in postmortem samples,30,42,43 suggesting
that postmortem ﬁndings are relevant to in vivo disease
processes. This last point is crucial, because these eQTL
targets could be the next generation of biomarkers. eQTL
biomarkers have the added beneﬁt of not only beingmolec-
ular but havingmapped genotype proﬁles, whichmight be
easier to assay than a molecular marker. Identifying
biomarkers that could further classify preclinical subgroups
and identify subclasses of rapid converters would help
signiﬁcantly reduce the cost of drug trials.
Third, by coupling SNP variation with changes in expres-
sion, we are able to map the neurobiological consequences
of our genetic ﬁndings. We began this screen because we
were frustratedwith our ownandothers’ efforts inmapping
novel risk factors for late onset Alzheimer disease. As of
2006, 355 additional candidate genes for LOAD have been
examined.44Of the subset of genes providing enough infor-
mation for meta-analysis, only ~20% had variants that
replicated. The majority of the replicated risk variants
werenoncoding; thus, thebiological consequences of those
changes are unknown.We felt that examining downstream
functionality of putative risk variants would help in distin-
guishing between true risk variants and those that were
merely markers of disease. Clearly, our efforts have had
some success, in that we are able to distinguish the genetic
effects of GSTO 2, the true risk gene, from GSTO 1, which
most likely associated with risk only because of high LD.
Fourth, although not crucial for detection of all effects, it
was important that our study sampled disease tissue. In
this study, over half the LOAD-associated effects that we
detected were not seen in our screen using control tissue.7
This could be due to differences in power between the ﬁrst
Listed are all of the transcripts with greater than 134 links (see Supple-
mental Data). Transcripts correlated with SNP genotype are highlighted
in bold. Cluster number (cluster), probe number from the Illumina
RefSeq-8 chip (Probe ID), transcript name from the Illumina RefSeq-8
chip (Name), Entrez gene identity number (Entrez), and the number of tran-
scripts linked to the target (No. Links) are given. All eQTL transcripts high-
lighted in bold have a significant diagnosis interaction (a ¼ 0.05), have
SNPs mapping in trans, and are differentially expressed between cases
and controls (SAM FDR < 0.1%), with the exception of MGC10812, which
met other the criteria but was not differentially expressed.rican Journal of Human Genetics 84, 445–458, April 10, 2009 455
Figure 3. Cluster 2 C6orf29 Network
Diagrammed in the figure are the predicted
transcript relationships given from our
analysis using NEO25 to impart direction-
ality on the transcript-transcript correla-
tions that we predicted from HQCUT22 for
the transcripts in cluster 2. For clarity,
only transcripts that had correlations with
SNP genotype and an interaction with
C6orf29 are listed (25% of cluster 2). In
the figure, SNP-transcript relationships are
given by dashed arrows and transcript-tran-
script relationships by solid arrows. Tran-
scripts are indicated by circles, gray circles
indicating transcripts where there was
a significant interaction with diagnosis in
the eQTL analysis and white circles indi-
cating no significant interaction term. Bidi-
rectional arrows indicate a feedback loop
between the two transcripts analyzed as
predicted by NEO analysis. Bidirectional
arrows divided by black circles indicate
that NEO predicted an unmapped hidden
confounder in the analysis of the relation-
ship between the two transcripts.screen and our second screen, which was approximately
double the sample size; however, there is the possibility
that there are effects speciﬁc to disease tissue. To examine
these outcomes, we performed a bootstrap analysis to
create from the control cohort data a data set that was
equal to the total cohort sample size in our LOAD screen
(n ¼ 364). Comparison of the permuted control data set
to our entire cohort showed that there were few differences
in the proﬁles of the two samples (see Table S3). We then
tested whether within this larger control cohort we could
detect our LOAD effects. We stratiﬁed the results into those
that had a signiﬁcant interaction term in our 2 df model
(LOAD set n ¼ 665, a ¼ 0.05) and those that were signiﬁ-
cant for allele dosage but did not have a diagnosis effect
(non-LOAD set n ¼ 1820, a ¼ 0.05). The bootstrap sample
captured all of the non-LOAD set effects at an a ¼ 0.001
and 95% at an a ¼ 1 3 107, which was the minimum
p value that is able to survive the permutation correction.
We were able to detect a much smaller portion of the
effects with a signiﬁcant interaction term, capturing only
66% of the LOAD set at an a ¼ 0.001. Results are shown
in Figure 4 and Tables S3 and S4. This suggests that
mapping disease-associated regulatory loci is more efﬁcient
and effective if the sampling cohort includes samples with
known disease phenotypes; however, it is of note that we
did capture LOAD effects in control tissue; thus, for prelim-
inary screens, disease phenotypes might not be an issue.
Finally, the full public release of these data constitutes
a resource to the community of researchers working on
this prevalent and devastating disease. The data ﬁles and
sample information used in generating the analysis for
this paper are available at the website of A.J.M. Additional456 The American Journal of Human Genetics 84, 445–458, April 10genotype ﬁles are available at the Translational Genomics
Research Institute website. Additional expression data
and information have been deposited in NCBI’s Gene
Expression Omnibus (GEO GSE15222). DNA from the
samples employed in this screen is available on request
through the National Cell Repository for Alzheimer’s
Disease for ﬁne mapping of particular effects.
Supplemental Data
Supplemental Data include Supplemental Acknowledgments,
three ﬁgures, and four tables and can be found with this article on-
line at http://www.ajhg.org/.
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Figure 4. SNP-Transcripts Specific to Disease Are More Likely
to Be Discovered in a Cohort with Disease-Specific Samples
The proportion of effects that we could detect from our current
study, utilizing brains from LOAD cases and nondemented controls,
in a sample of equal size (n¼ 364) generated by bootstrapping our
control data is plotted. The alpha cutoff is plotted on the x axis and
the proportion of effects detected is on the y axis. The proportion
of eQTLs detected of those that showed a significant diagnosis
interaction (a ¼ 0.05 for the interaction term in our 2 df model)
is shown by the filled circles and solid line. The proportion de-
tected of those that did not have a significant diagnosis effect
(interaction term p value R 0.05) is shown by the open circles
and dotted line. Counts and alphas used to generate this graph
are given in Table S4.The AmNational Cell Repository for Alzheimer’s Disease, http://ncrad.iu.
edu/
NACC protocols, http://www.alz.washington.edu
NCBI’s Gene Expression Omnibus, http://www.ncbi.nlm.nih.gov/
geo/
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